Safety and tolerability in the MORE trial

Cutis

Volumn 78, Issue 1 SUPPL., 2006, Pages 19-25

  Wolf Jr , John E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; TREATMENT OUTCOME;

EID: 33748942108     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Egan N, Loesche C, Baker M. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68(suppl4):20-24.
2. Koo J. How do you foster medication adherence for better acne vulgaris management? Skinmed. 2003;2:229-233.
3. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
4. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726-735.
5. Campbell JL Jr, Weiss JS. The results of the MORE trial: overview. Cutis. 2006;78(suppl 1):5-11.
6. Stein Gold L. The MORE trial: effectiveness of adapalene gel 0.1% in real-world dermatology practices. Cutis. 2006;78(suppl 1):12-18.
7. Cook-Bolden F. Subject preferences for acne treatments containing adapalene gel 0.1%: results of the MORE trial. Cutis. 2006;78(suppl 1):26-33.
8. Waugh J, Noble S, Scott LJ. Adapalene: a review of its use in the treatment of acne vulgaris. Drugs. 2004;64:1465-1478.
9. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis. 2005;75:289-293.
10. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49(suppl 3):S211-S217.
11. Thiboutot DM, Shalita AR, Yamauchi PS, et al, on behalf of the Differin Study Group. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4:138-146.
12. Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? a comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol. 2003;49(suppl 3):S218-S226.
13. Baker M, Tuley M, Busdiecker L, et al. Adapalene gel 0.1% is effective and well tolerated in acne patients in a dermatology practice setting. Cutis. 2001;68(suppl 4):41-47.
14. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139(suppl 52):34-40.